{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:54:46Z","timestamp":1794887686501,"version":"4.9.1"},"reference-count":120,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology (Taiwan)","doi-asserted-by":"publisher","award":["110-2314-B-281-007-MY3"],"award-info":[{"award-number":["110-2314-B-281-007-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology (Taiwan)","doi-asserted-by":"publisher","award":["CGH-MR-A10905"],"award-info":[{"award-number":["CGH-MR-A10905"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology (Taiwan)","doi-asserted-by":"publisher","award":["CGH-MR-A11311"],"award-info":[{"award-number":["CGH-MR-A11311"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cathay research grant","award":["110-2314-B-281-007-MY3"],"award-info":[{"award-number":["110-2314-B-281-007-MY3"]}]},{"name":"Cathay research grant","award":["CGH-MR-A10905"],"award-info":[{"award-number":["CGH-MR-A10905"]}]},{"name":"Cathay research grant","award":["CGH-MR-A11311"],"award-info":[{"award-number":["CGH-MR-A11311"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by the small intestine upon food intake. GLP-1 enhances insulin secretion, suppresses glucagon release, and promotes satiety, resulting in reduced food consumption and subsequent weight loss. Endogenous GLP-1 has a very short half-life and is rapidly degraded by the enzyme dipeptidyl-peptidase-IV (DPP-4). To address this limitation, GLP-1 receptor agonists (GLP-1RAs) and DPP-4 inhibitors (DPP-4is) were developed and have demonstrated potency in clinical practice. In recent years, GLP-1RA and DPP4-i therapies are known to have pleiotropic effects, such as a reduction in oxidative stress, autophagy regulation, metabolic reprogramming, enhancement of anti-inflammatory signaling, regulation of gene expression, and being neuroprotective. These effects imply a therapeutic perspective for GLP-1RA and DPP-4i therapies in neuropathic pain treatment. Preclinical and clinical studies increasingly support the hypothesis that these therapies may alleviate neuropathic pain by targeting multiple mechanisms that induce neuropathic pain, such as inflammation, oxidative stress, and mitochondrial dysfunction. This review explores the mechanisms by which GLP-1RAs and DPP-4is alleviate neuropathic pain. It also highlights current advancements in incretin research, focusing on the therapeutic effects of GLP-1RAs and DPP-4-is for neuropathic pain.<\/jats:p>","DOI":"10.3390\/biom15050622","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T08:28:11Z","timestamp":1746174491000},"page":"622","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-3736","authenticated-orcid":false,"given":"Yaswanth","family":"Kuthati","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Cathay General Hospital, Taipei 10630, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Naga Goutham","family":"Davuluri","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9898-9950","authenticated-orcid":false,"given":"Chih-Shung","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Cathay General Hospital, Taipei 10630, Taiwan"},{"name":"Graduate Institute of Medical Science, National Defense Medical Center, Taipei 11467, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11916-025-01384-1","article-title":"Neuropathic Pain: A Comprehensive Bibliometric Analysis of Research Trends, Contributions, and Future Directions","volume":"29","author":"Leoni","year":"2025","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11916-017-0629-5","article-title":"Neuropathic Pain: Central vs. Peripheral Mechanisms","volume":"21","author":"Meacham","year":"2017","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuron.2006.09.021","article-title":"Mechanisms of neuropathic pain","volume":"52","author":"Campbell","year":"2006","journal-title":"Neuron"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Nashtahosseini, Z., Eslami, M., Paraandavaji, E., Haraj, A., Dowlat, B.F., Hosseinzadeh, E., Oksenych, V., and Naderian, R. (2025). Cytokine Signaling in Diabetic Neuropathy: A Key Player in Peripheral Nerve Damage. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030589"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1523\/JNEUROSCI.4703-13.2014","article-title":"Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity","volume":"34","author":"Gong","year":"2014","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"172835","DOI":"10.1016\/j.ejphar.2019.172835","article-title":"Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats","volume":"866","author":"Shekunova","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gallwitz, B. (2019). Clinical Use of DPP-4 Inhibitors. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00389"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10194-025-01979-4","article-title":"Advances in GLP-1 receptor agonists for pain treatment and their future potential","volume":"26","author":"He","year":"2025","journal-title":"J. Headache Pain"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kuthati, Y., Rao, V.N., Busa, P., and Wong, C.S. (2021). Teneligliptin Exerts Antinociceptive Effects in Rat Model of Partial Sciatic Nerve Transection Induced Neuropathic Pain. Antioxidants, 10.","DOI":"10.3390\/antiox10091438"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kuthati, Y., Rao, V.N., Huang, W.H., Busa, P., and Wong, C.S. (2023). Teneligliptin Co-Infusion Alleviates Morphine Tolerance by Inhibition of Spinal Microglial Cell Activation in Streptozotocin-Induced Diabetic Rats. Antioxidants, 12.","DOI":"10.3390\/antiox12071478"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lee, S.-O., Kuthati, Y., Huang, W.-H., and Wong, C.-S. (2024). Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord. Cells, 13.","DOI":"10.3390\/cells13221857"},{"key":"ref_14","first-page":"e72080","article-title":"Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders","volume":"16","author":"Olukorode","year":"2024","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., and Zhang, Y. (2021). GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.721135"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.tem.2025.01.002","article-title":"Glucagon-like peptide-1 receptor agonism and end-organ protection","volume":"36","author":"Daniels","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1152\/jn.00228.2024","article-title":"Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy","volume":"133","author":"Dhanapalaratnam","year":"2025","journal-title":"J. Neurophysiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s10194-024-01821-3","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: A systematic review","volume":"25","author":"Halloum","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Serrano Afonso, A., Carnaval, T., and Videla C\u00e9s, S. (2021). Combination Therapy for Neuropathic Pain: A Review of Recent Evidence. J. Clin. Med., 10.","DOI":"10.20944\/preprints202106.0200.v2"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12974-018-1222-5","article-title":"Molecular and cellular identification of the immune response in peripheral ganglia following nerve injury","volume":"15","author":"Lindborg","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainresbull.2011.10.004","article-title":"Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases","volume":"87","author":"Smith","year":"2012","journal-title":"Brain Res. Bull."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s10020-023-00647-0","article-title":"Excitatory and inhibitory neuronal signaling in inflammatory and diabetic neuropathic pain","volume":"29","author":"Breitinger","year":"2023","journal-title":"Mol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"fcad356","DOI":"10.1093\/braincomms\/fcad356","article-title":"Role of oxidative stress in neurodegenerative disorders: A review of reactive oxygen species and prevention by antioxidants","volume":"6","author":"Houldsworth","year":"2024","journal-title":"Brain Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3892\/mmr.2024.13387","article-title":"Research progress on antioxidants and protein aggregation inhibitors in cataract prevention and therapy (Review)","volume":"31","author":"Wang","year":"2025","journal-title":"Mol. Med. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Carrasco, C., Naziro\u01e7lu, M., Rodr\u00edguez, A.B., and Pariente, J.A. (2018). Neuropathic Pain: Delving into the Oxidative Origin and the Possible Implication of Transient Receptor Potential Channels. Front. Physiol., 9.","DOI":"10.3389\/fphys.2018.00095"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Espinoza, N., and Papadopoulos, V. (2025). Role of Mitochondrial Dysfunction in Neuropathy. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26073195"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gaggini, M., Sabatino, L., Suman, A.F., Chatzianagnostou, K., and Vassalle, C. (2025). Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology. Cells, 14.","DOI":"10.3390\/cells14050387"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"106550","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Deacon, C.F. (2019). Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00080"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"107503","DOI":"10.1016\/j.pharmthera.2020.107503","article-title":"Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions","volume":"209","author":"Shao","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Monti, G., Gomes Moreira, D., Richner, M., Mutsaers, H.A.M., Ferreira, N., and Jan, A. (2022). GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. Cells, 11.","DOI":"10.3390\/cells11132023"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zeng, N., Cutts, E.J., Lopez, C.B., Kaur, S., Duran, M., Virkus, S.A., and Hardaway, J.A. (2021). Anatomical and Functional Characterization of Central Amygdala Glucagon-Like Peptide 1 Receptor Expressing Neurons. Front. Behav. Neurosci., 15.","DOI":"10.3389\/fnbeh.2021.724030"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/cne.24905","article-title":"A novel mouse model of glucagon-like peptide-1 receptor expression: A look at the brain","volume":"528","author":"Graham","year":"2020","journal-title":"J. Comp. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/en.2011-0174","article-title":"Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4","volume":"152","author":"Kanoski","year":"2011","journal-title":"Endocrinology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1210\/en.2017-00812","article-title":"Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization","volume":"159","author":"Jensen","year":"2017","journal-title":"Endocrinology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/en.2006-0153","article-title":"Glucagon-Like Peptide-1 (GLP-1) Receptors Expressed on Nerve Terminals in the Portal Vein Mediate the Effects of Endogenous GLP-1 on Glucose Tolerance in Rats","volume":"148","author":"Vahl","year":"2007","journal-title":"Endocrinology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cmet.2020.05.001","article-title":"GLP-1 Receptor Signaling in Astrocytes Regulates Fatty Acid Oxidation, Mitochondrial Integrity, and Function","volume":"31","author":"Timper","year":"2020","journal-title":"Cell Metab."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hunter, K., and H\u00f6lscher, C. (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci., 13.","DOI":"10.1186\/1471-2202-13-33"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: Mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1172\/JCI78371","article-title":"Glucagon-like peptide-1 receptors in the brain: Controlling food intake and body weight","volume":"124","author":"Baggio","year":"2014","journal-title":"J. Clin. Invest."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1172\/JCI72434","article-title":"Neuronal GLP1R mediates liraglutide\u2019s anorectic but not glucose-lowering effect","volume":"124","author":"Sisley","year":"2014","journal-title":"J. Clin. Invest."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Li, Y., Chigurupati, S., Holloway, H.W., Mughal, M., Tweedie, D., Bruestle, D.A., Mattson, M.P., Wang, Y., Harvey, B.K., and Ray, B. (2012). Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032008"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.cmet.2024.09.003","article-title":"GLP-1 programs the neurovascular landscape","volume":"36","author":"Chen","year":"2024","journal-title":"Cell Metab."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Tong, G., Peng, T., Chen, Y., Sha, L., Dai, H., Xiang, Y., Zou, Z., He, H., and Wang, S. (2022). Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K\/AKT\/mTOR Signaling Pathway. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.901559"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MED.0b013e3280a02f65","article-title":"Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus","volume":"14","author":"Rosenstock","year":"2007","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kir\u00e1ly, K., Kozsurek, M., Luk\u00e1csi, E., Barta, B., Alp\u00e1r, A., Bal\u00e1zsa, T., Fekete, C., Szabon, J., Helyes, Z., and B\u00f6lcskei, K. (2018). Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-21799-8"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.peptides.2017.12.020","article-title":"Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion","volume":"100","author":"McKillop","year":"2018","journal-title":"Peptides"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","article-title":"Circulation and degradation of GIP and GLP-1","volume":"36","author":"Deacon","year":"2004","journal-title":"Horm. Metab. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13300-014-0061-3","article-title":"Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: A systematic review and mixed treatment comparison","volume":"5","author":"Craddy","year":"2014","journal-title":"Diabetes Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.beem.2009.03.008","article-title":"Exenatide and liraglutide: Different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results","volume":"23","author":"Madsbad","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.diabres.2010.07.006","article-title":"DPP-4 inhibitors: What may be the clinical differentiators?","volume":"90","author":"Gerich","year":"2010","journal-title":"Diabetes Res. Clin. Pr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1089\/dia.2011.0076","article-title":"Exenatide once-weekly clinical development: Safety and efficacy across a range of background therapies","volume":"13","author":"Stonehouse","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/dom.12251","article-title":"The extra-pancreatic effects of GLP-1 receptor agonists: A focus on the cardiovascular, gastrointestinal and central nervous systems","volume":"16","author":"Seufert","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Cifuentes, L., Camilleri, M., and Acosta, A. (2021). Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity-Therapeutic Implications. Nutrients, 13.","DOI":"10.3390\/nu13041158"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_58","first-page":"239","article-title":"Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists","volume":"6","author":"Uccellatore","year":"2015","journal-title":"Diabetes Ther. Res. Treat. Educ. Diabetes Relat. Disord."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Gilbert, M.P., and Pratley, R.E. (2020). GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00178"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_61","unstructured":"Latif, W., Lambrinos, K.J., Patel, P., and Rodriguez, R. (2025). Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs). StatPearls, StatPearls Publishing."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Liu, C., Wu, T., and Ren, N. (2023). Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1268619"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s44158-024-00204-z","article-title":"Neuropathic pain, antidepressant drugs, and inflammation: A narrative review","volume":"4","author":"Catalisano","year":"2024","journal-title":"J. Anesth. Analg. Crit. Care"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., and Berenbaum, F. (2022). Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-05323-7"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"109806","DOI":"10.1016\/j.diabres.2022.109806","article-title":"Glucagon-like peptide-1 receptor agonist attenuates diabetic neuropathic pain via inhibition of NOD-like receptor protein 3 inflammasome in brain microglia","volume":"186","author":"Zhang","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/bph.13720","article-title":"Morroniside, a secoiridoid glycoside from Cornus officinalis, attenuates neuropathic pain by activation of spinal glucagon-like peptide-1 receptors","volume":"174","author":"Xu","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"107748","DOI":"10.1016\/j.neuropharm.2019.107748","article-title":"The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke","volume":"158","author":"Yang","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9923537","DOI":"10.1155\/2021\/9923537","article-title":"Microglial Activation of GLP-1R Signaling in Neuropathic Pain Promotes Gene Expression Adaption Involved in Inflammatory Responses","volume":"2021","author":"Ma","year":"2021","journal-title":"Neural Plast."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.metabol.2012.03.002","article-title":"GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases","volume":"61","author":"Hendarto","year":"2012","journal-title":"Metab. Clin. Exp."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/cns.13694","article-title":"Spinal microglial \u03b2-endorphin signaling mediates IL-10 and exenatide-induced inhibition of synaptic plasticity in neuropathic pain","volume":"27","author":"Ma","year":"2021","journal-title":"CNS Neurosci. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"110520","DOI":"10.1016\/j.intimp.2023.110520","article-title":"Potential anxiolytic and antidepressant-like effects of luteolin in a chronic constriction injury rat model of neuropathic pain: Role of oxidative stress, neurotrophins, and inflammatory factors","volume":"122","author":"Mokhtari","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4239\/wjd.v15.i4.724","article-title":"Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome","volume":"15","author":"Zhang","year":"2024","journal-title":"World J. Diabetes"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Khan, T., Waseem, R., Zehra, Z., Aiman, A., Bhardwaj, P., Ansari, J., Hassan, M.I., and Islam, A. (2022). Mitochondrial Dysfunction: Pathophysiology and Mitochondria-Targeted Drug Delivery Approaches. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122657"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Pan, X., Xu, S., Li, J., and Tong, N. (2020). The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2\/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.599355"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., and LeRoith, D. (2023). Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1148209"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/jnc.14336","article-title":"Liraglutide ameliorated peripheral neuropathy in diabetic rats: Involvement of oxidative stress, inflammation and extracellular matrix remodeling","volume":"146","author":"Moustafa","year":"2018","journal-title":"J. Neurochem."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Noguchi, T., Katoh, H., Nomura, S., Okada, K., and Watanabe, M. (2024). The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype. Front. Neurosci., 18.","DOI":"10.3389\/fnins.2024.1342944"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Lambadiari, V., Thymis, J., Kouretas, D., Skaperda, Z., Tekos, F., Kousathana, F., Kountouri, A., Balampanis, K., Parissis, J., and Andreadou, I. (2021). Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes. Antioxidants, 10.","DOI":"10.3390\/antiox10091379"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9432965","DOI":"10.1155\/2019\/9432965","article-title":"The Emerging Perspective of Morphine Tolerance: MicroRNAs","volume":"2019","author":"Zhang","year":"2019","journal-title":"Pain Res. Manag."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.metabol.2012.09.004","article-title":"A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients","volume":"62","author":"Sasaki","year":"2013","journal-title":"Metab. Clin. Exp."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vph.2018.05.010","article-title":"Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases","volume":"109","author":"Xie","year":"2018","journal-title":"Vasc. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1210\/clinem\/dgae783","article-title":"Impact of DPP-4 Inhibitors on Interleukin Levels in Type 2 Diabetes Mellitus","volume":"110","author":"Feng","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1464-5491.2004.01296.x","article-title":"C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones","volume":"21","author":"Nesto","year":"2004","journal-title":"Diabet. Med. A J. Br. Diabet. Assoc."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"514","DOI":"10.30699\/jambs.31.149.514","article-title":"Potential Role of Oxidative Stress on the Pathophysiology of Neuropathic Pain in the Inflammatory Diseases","volume":"31","author":"Ghasemi","year":"2023","journal-title":"J. Adv. Med. Biomed. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"105280","DOI":"10.1016\/j.phrs.2020.105280","article-title":"Neuroinflammation, oxidative stress and their interplay in neuropathic pain: Focus on specialized pro-resolving mediators and NADPH oxidase inhibitors as potential therapeutic strategies","volume":"162","author":"Pinho","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Oh, Y.S., and Jun, H.S. (2017). Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010026"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1007\/s12035-023-03342-7","article-title":"Oxidative Stress in Diabetic Peripheral Neuropathy: Pathway and Mechanism-Based Treatment","volume":"60","author":"Lin","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1089\/ars.2021.0152","article-title":"Oxidative Stress and Mitochondrial Dysfunction Associated with Peripheral Neuropathy in Type 1 Diabetes","volume":"37","author":"Eftekharpour","year":"2022","journal-title":"Antioxid. Redox Signal."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.7150\/thno.86831","article-title":"Targeting redox imbalance in neurodegeneration: Characterizing the role of GLP-1 receptor agonists","volume":"13","author":"Ghosh","year":"2023","journal-title":"Theranostics"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ibneur.2023.11.007","article-title":"Superoxide dismutase and neurological disorders","volume":"16","author":"Chidambaram","year":"2024","journal-title":"IBRO Neurosci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Luna-Marco, C., de Mara\u00f1on, A.M., Hermo-Argibay, A., Rodriguez-Hernandez, Y., Hermenejildo, J., Fernandez-Reyes, M., Apostolova, N., Vila, J., Sola, E., and Morillas, C. (2023). Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox Biol., 66.","DOI":"10.1016\/j.redox.2023.102849"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Wu, Q., Li, D., Huang, C., Zhang, G., Wang, Z., Liu, J., Yu, H., Song, B., Zhang, N., and Li, B. (2022). Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists. Biomed. Pharmacother., 153.","DOI":"10.1016\/j.biopha.2022.113517"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41392-024-01839-8","article-title":"Mitochondrial dysfunction: Mechanisms and advances in therapy","volume":"9","author":"Zong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Yang, C., Zhao, X., An, X., Zhang, Y., Sun, W., Zhang, Y., Duan, Y., Kang, X., Sun, Y., and Jiang, L. (2023). Axonal transport deficits in the pathogenesis of diabetic peripheral neuropathy. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1136796"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-025-02608-9","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: Historical development and future challenges","volume":"24","author":"Westermeier","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Yip, J.M.X., Chiang, G.S.H., Lee, I.C.J., Lehming-Teo, R., Dai, K., Dongol, L., Wang, L.Y.-T., Teo, D., Seah, G.T., and Lehming, N. (2025). Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26010364"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4","DOI":"10.53941\/hm.2025.100004","article-title":"AMPK-Mediated Multi-Organ Protective Effects of GLP-1 Receptor Agonists","volume":"2","author":"Wang","year":"2025","journal-title":"Health Metab."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Hong, C.T., Chen, J.H., and Hu, C.J. (2024). Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease. J. Biomed. Sci., 31.","DOI":"10.1186\/s12929-024-01090-x"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/s12276-024-01342-8","article-title":"GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation","volume":"56","author":"Go","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Diz-Chaves, Y., Mastoor, Z., Spuch, C., Gonz\u00e1lez-Mat\u00edas, L.C., and Mallo, F. (2022). Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179583"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1900\/RDS.2011.8.418","article-title":"GLP-1, the gut-brain, and brain-periphery axes","volume":"8","author":"Cabou","year":"2011","journal-title":"Rev. Diabet. Stud. RDS"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"111999","DOI":"10.1016\/j.diabres.2025.111999","article-title":"Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight\/obesity: A systematic review and network meta-analysis","volume":"222","author":"Wen","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpain.2009.06.012","article-title":"Central sensitization: A generator of pain hypersensitivity by central neural plasticity","volume":"10","author":"Latremoliere","year":"2009","journal-title":"J. Pain"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Fujita, S., Ushio, S., Ozawa, N., Masuguchi, K., Kawashiri, T., Oishi, R., and Egashira, N. (2015). Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141921"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e024065","DOI":"10.1136\/bmjopen-2018-024065","article-title":"Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: Protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial","volume":"9","author":"Gudbergsen","year":"2019","journal-title":"BMJ Open"},{"key":"ref_108","unstructured":"Collins, L., and Costello, R.A. (2025). Glucagon-Like Peptide-1 Receptor Agonists. StatPearls, StatPearls Publishing."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10557-024-07647-0","article-title":"Glucagon-Like Peptide-1 Receptor Agonists for Abdominal Aortic Aneurysm?","volume":"39","author":"Birnbaum","year":"2025","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11154-023-09807-3","article-title":"Effects of GLP-1 receptor agonists on neurological complications of diabetes","volume":"24","author":"Ariza","year":"2023","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Jiang, X., Li, J., Yao, X., Ding, H., Gu, A., and Zhou, Z. (2024). Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer\u2019s disease: A narrative review. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1361651"},{"key":"ref_113","first-page":"121","article-title":"Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: A new opportunity?","volume":"32","author":"Meurot","year":"2022","journal-title":"J. Orthop. Transl."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/17512433.2024.2421872","article-title":"SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation","volume":"17","author":"Lopes","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1038\/s41467-020-17556-z","article-title":"Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans","volume":"11","author":"Baggio","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2147\/DMSO.S375559","article-title":"The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors","volume":"15","author":"Dong","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Darsalia, V., Johansen, O.E., Lietzau, G., Nystr\u00f6m, T., Klein, T., and Patrone, C. (2019). Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.00493"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/1673-5374.224365","article-title":"Tackling dipeptidyl peptidase IV in neurological disorders","volume":"13","author":"Leggio","year":"2018","journal-title":"Neural Regen. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e2435247","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and Opioid Overdose Risk in Patients with Type 2 Diabetes and Opioid Use Disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/5\/622\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:22:16Z","timestamp":1760030536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/5\/622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":120,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["biom15050622"],"URL":"https:\/\/doi.org\/10.3390\/biom15050622","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]}}}